Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Robert Behrens (NPI 1215999800)

Field	Value
Entity Type	Individual
Organization	Robert Behrens
Address	1221 Pleasant St
City	Des Moines
State	IA
ZIP	50309
Taxonomy	Medical Oncology Physician
NPI Enumerated	April 6, 2006

Payer Source	Total Paid
Medicare	$5.2M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the dataset: total Medicare revenue is $5.2M and there is no Medicaid billing on file, so analyses of payer mix and revenue risk should treat Medicare as the dominant (in practice sole) public payer exposure. That concentration increases sensitivity to Medicare reimbursement and utilization patterns rather than state Medicaid dynamics.

Revenue is highly concentrated in a small set of drugs and infusion services: the precomputed top 3 Medicare codes account for 78.4% of the provider's total Medicare revenue, led by J9271 (58.7% of Medicare revenue), followed by J9299 (16.4%) and Q5126 (3.4%). This means a few high‑cost oncology agents drive most of the practice’s billings and negotiating leverage.

The clinical profile is consistent with a high‑volume medical oncology infusion practice: the top codes are J9271 and J9299 (pembrolizumab and nivolumab immunotherapy agents) and Q5126 (a bevacizumab biosimilar), and high counts for chemotherapy administration codes such as 96413 indicate routine in‑office IV infusions and complex oncologic drug delivery. Together these codes point to outpatient infusion services and immunotherapy as the core service line.

The provider is a national outlier for pembrolizumab use: J9271 generates $3M in Medicare revenue (58.7% of this provider’s Medicare revenue) and ranks #4 of 1841 providers nationally (100th percentile; extreme outlier), identifying the clinician as a top‑tier national user of that agent. By contrast, J9299 (nivolumab) yields $826.1K (16.4%) and ranks #52 of 505 (90th percentile; typical, unremarkable volume), so dominance appears concentrated on pembrolizumab specifically rather than uniformly across all checkpoint inhibitors.

Multiple administration and E/M codes are also extreme outliers, reinforcing a high throughput infusion operation: 96413 ranks #23 of 7514 (100th percentile; extreme outlier), 96367 ranks #30 of 4032 (99th percentile; extreme outlier), 96417 ranks #23 of 3014 (99th percentile; extreme outlier), and 99214 ranks #7841 of 479517 (98th percentile; extreme outlier). These high ranks for both drug administration and office E/M work suggest sustained, above‑typical volumes across infusion encounters and follow‑up visits.

The practice shows meaningful adoption of biosimilars alongside originator biologics: Q5126 (bevacizumab‑maly) produced $170K and Q5118 (bevacizumab‑bvzr) produced $146K, with Q5118 ranking #14 of 161 providers nationally (92th percentile; notably above typical national volume for this code). Multiple Q‑codes for biosimilars (Q5126, Q5118, Q5112, Q5115) appear in the top billing list, indicating a mix of biosimilar and biosimilar alternatives in infusion regimens rather than exclusive use of originators.

The single largest revenue line is a single drug: J9271 alone accounts for $3M of the provider’s Medicare revenue. Given total Medicare revenue of $5.2M, that concentration means performance and utilization of pembrolizumab will disproportionately affect year‑to‑year revenue and should be a focus for contract and utilization reviews.

Provider tenure is long enough to establish an entrenched practice footprint: the NPI was enumerated on 2006-04-06 (~20 years ago), which combined with the high and sustained billing volumes for infusions and select drugs suggests an established oncology infusion operation rather than a recent entrant or low‑volume practitioner.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

80 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	70,400	$40	$3M
J9299	Injection, nivolumab, 1 mg	34,420	$20	$826.1K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	3,270	$50	$170K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	5,840	$30	$146K
Q5112	Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg	3,520	$40	$137.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,300	$90	$122.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	3,000	$40	$108K
J0897	Injection, denosumab, 1 mg	5,760	$20	$103.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,160	$80	$90.3K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	2,430	$40	$85K

Showing 1–10 of 80

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 80 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Robert Behrens — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

80 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	30	17,200	$40	$902.3K
J9299	2	10	18,700	$20	$527.6K
Q5112	2	10	4,000	$40	$155.6K
Q5126	2	10	3,270	$50	$146.6K
Q5118	2	10	5,840	$20	$137.4K
J1569	5	10	2,680	$40	$133.6K
Q5122	2	10	530	$100	$75.4K
J0897	36	190	1,920	$20	$74.1K
Q5115	3	10	1,790	$30	$71.4K
J2506	7	20	440	$80	$38.9K

Showing 1–10 of 80

Related Providers

Other providers that share a Tax Identification Number (TIN) with Robert Behrens, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
State University Of Iowa	IA	Family Medicine Physician	$0	$103.8M
State University Of Iowa	IA	General Acute Care Hospital	$0	$90.4M
State University Of Iowa	IA	Dentist	$0	$25.8M
Somc Medical Care Foundation, Inc.	OH	Family Medicine Physician	$0	$25.3M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0

Nearby Providers

Other providers in the same ZIP code as Robert Behrens, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Central Iowa Hospital Corporation	IA	General Acute Care Hospital	$0	$58M
Eyerly Ball Community Mental Health Services	IA	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$57M
City Of Des Moines Iowa	IA	Land Ambulance	$1.1M	$47.2M
Orchard Place	IA	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$30.5M
Woodward Youth Corporation	IA	Community/Behavioral Health Agency	$0	$28.2M
Dhs-targeted Case Management	IA	Case Management Agency	$0	$26.2M
Central Iowa Hospital Corporation	IA	Pediatrics Physician	$0	$25.4M
Central Iowa Hospital Corporation	IA	Emergency Medicine Physician	$0	$13.1M
Orchard Place	IA	Adolescent and Children Mental Health Clinic/Center	$0	$6.6M
Youth Emergency Services & Shelter Of Iowa	IA	Voluntary or Charitable Agency	$0	$4.7M

Robert Behrens — Billing Profile & Reimbursement Data

Sign up for Robert Behrens — Billing Profile & Reimbursement Data policy alerts

Robert Behrens — Billing Profile & Reimbursement Data

Sign up for Robert Behrens — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References